WEBULL
News
PDSB
0.6100
-5.86%
-0.0380
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Integer Holdings (ITGR) and Tonix Pharma (TNXP)
TipRanks · 7h ago
Weekly Report: what happened at PDSB last week (0216-0220)?
Weekly Report · 13h ago
PDS Biotechnology Updates VERSATILE-003 Trial for Accelerated Approval
TipRanks · 3d ago
PDS announces adoption of protocol amendment to Phase 3 VERSATILE-003 trial
TipRanks · 3d ago
PDS Biotechnology Adopts Amended Protocol To Its Phase 3 VERSATILE-003 Clinical Study
Benzinga · 3d ago
PDS Biotech Adds PFS Interim Primary Endpoint to Phase 3 VERSATILE-003 Trial for PDS0101 in HPV16-Positive Head and Neck Cancer
Reuters · 3d ago
PDS BIOTECHNOLOGY CORP - MEDIAN OVERALL SURVIVAL REMAINS PRIMARY ENDPOINT FOR FULL APPROVAL
Reuters · 3d ago
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
Barchart · 3d ago
Weekly Report: what happened at PDSB last week (0209-0213)?
Weekly Report · 02/16 09:06
Weekly Report: what happened at PDSB last week (0202-0206)?
Weekly Report · 02/09 09:06
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 02/04 12:05
Weekly Report: what happened at PDSB last week (0126-0130)?
Weekly Report · 02/02 09:06
PDS Biotechnology Highlights Promising Phase 2 Prostate Cancer Data
TipRanks · 01/28 14:18
PDS announces presentation of preliminary Phase 2 results on PDS01ADC
TipRanks · 01/28 13:56
PDS Biotechnology Presents Results Of National Cancer Institute-Led Study Of Investigational Interleukin-12 Tumor Targeted Immunocytokine, PDS01ADC, At AACR Special Conference
Benzinga · 01/28 13:48
PDS Biotech Reports Promising Phase 2 Results for PDS01ADC in Metastatic Prostate Cancer
Reuters · 01/28 13:45
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
Barchart · 01/28 07:45
Weekly Report: what happened at PDSB last week (0119-0123)?
Weekly Report · 01/26 09:06
More
Webull provides a variety of real-time PDSB stock news. You can receive the latest news about Pds Biotechnology Corporation through multiple platforms. This information may help you make smarter investment decisions.
About PDSB
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.